BioSpace News Archive

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study.

Bristol Myers Squibb announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer who had previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-1 therapy.

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence -enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer.

Takeda and Pfizer announced that the German Hodgkin Study Group will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology Annual Meeting and at the 29th European Hematology Association Annual Meeting.

Pfizer Inc. announced detailed overall survival results from the Phase 3 ECHELON-3 study of ADCETRIS® in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Summit Therapeutics Inc. announced that the Journal of the American Medical Association published a manuscript titled, “Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial.”

Y-mAbs Therapeutics, Inc. announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.

Nuvation Bio Inc. announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation ROS1 tyrosine kinase inhibitor, were published in the Journal of Clinical Oncology and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, Illinois.

Werewolf Therapeutics, Inc. announced new clinical data from the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINETM molecule, in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

ClearPoint Neuro, Inc. announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.